Vir Biotechnology, Inc.

Vir Biotechnology's Board of Directors increased its size from seven to eight members and appointed Timothy Coughlin, CPA, as a Class III director, effective immediately. Mr. Coughlin will serve until the 2028 annual meeting and also assume the role of Chair of the Audit Committee. As a non-employee director, he will receive standard cash and equity compensation, including stock options and restricted stock units, and has entered into a standard indemnity agreement with the company.

Vir Biotechnology announced that Saira Ramasastry departed from its Board of Directors and as Chair of the Audit Committee due to a business conflict, effective May 26, 2026. Following her departure, Robert More was appointed as the new Chair of the Audit Committee, and the Board size was reduced from eight to seven members. Additionally, at its 2026 Annual Meeting of Stockholders, the company's stockholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026.

Vir Biotechnology reported a net loss of $(125.7) million for the first quarter of 2026, a slight increase from $(121.0) million in the same period last year, though net loss per share improved to $(0.85). Total revenues significantly decreased to $(29) thousand. The company bolstered its liquidity with $162.3 million in net proceeds from a follow-on public offering in February 2026, bringing its total cash, cash equivalents, and investments to $809.3 million.

Vir Biotechnology reported its first quarter 2026 financial results, with a net loss of $125.7 million and a strong cash position of $809.3 million. The company highlighted significant corporate momentum, including the closing of its global strategic collaboration with Astellas for VIR-5500 in prostate cancer, with the first patient dosed in Phase 1 expansion cohorts. Additionally, Vir Bio will present complete Week 96 Phase 2 SOLSTICE data for its chronic hepatitis delta combination regimen at the upcoming EASL Congress, and expects its cash runway to extend into the second half of 2028.

Vir Biotechnology, Inc. announced that Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer, will be stepping down from his role. His departure is effective April 24, 2026. The company has begun the search for a new Chief Medical Officer.